Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Seven funds under Xingyin Fund hold a total of 254,400 shares of Tiger Med, with a floating profit of approximately 646,200 CNY based on the stock price increase [2][6]. - The top funds holding Tiger Med shares include: - Xingyin Smart Consumer Mixed Fund A (018990) holds 52,600 shares, representing 2.99% of the fund's net value, with a floating profit of about 133,600 CNY [3][7]. - Xingyin Stable Return Mixed Fund A (009205) holds 52,000 shares, representing 0.91% of the fund's net value, with a floating profit of about 132,100 CNY [4][8]. - Xingyin Prosperity Preferred Mixed Fund A (010124) holds 45,700 shares, representing 2.46% of the fund's net value, with a floating profit of about 116,100 CNY [4][8].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - One fund under Huatai Asset Management holds a significant position in Tiger Med. The Huatai Zijin Innovation Pioneer Mixed Fund (LOF) C (501202) reduced its holdings by 32,100 shares in the fourth quarter, now holding 175,300 shares, which represents 4.83% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund has reported a floating profit of approximately 445,300 CNY today and a total of 568,000 CNY during the three-day increase [2][5]. - The Huatai Zijin Innovation Pioneer Mixed Fund (LOF) C was established on July 17, 2020, with a current size of 189 million CNY. Year-to-date, it has experienced a loss of 2.41%, ranking 6181 out of 8898 in its category, while it has achieved a return of 27.77% over the past year, ranking 2487 out of 8181 [2][5].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Jianxin Fund has a significant holding in Tiger Med through the Jianxin CSI Innovative Drug Industry ETF (159835), which increased its stake by 34,700 shares in the fourth quarter, holding a total of 127,500 shares, representing 2.88% of the fund's net value [2][5]. - The ETF has generated a floating profit of approximately 323,800 CNY today and 413,100 CNY during the three-day increase [2][5]. - The Jianxin CSI Innovative Drug Industry ETF was established on March 11, 2021, with a current size of 251 million CNY. Year-to-date, it has experienced a loss of 6.97%, ranking 4791 out of 5563 in its category, while it has gained 7.64% over the past year, ranking 3433 out of 4429 [2][5]. Fund Manager Information - The fund manager of the Jianxin CSI Innovative Drug Industry ETF is Gong Jiajia, who has been in the position for 7 years and 36 days. The total asset size of the fund is 1.867 billion CNY, with the best return during the tenure being 44.21% and the worst being -58.77% [3][6][7].

Core Viewpoint - Tiger Med's stock price has increased by 5% on March 27, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xinda Australia Fund has a significant holding in Tiger Med, with the Xinda Health China Mixed A Fund (003291) holding 324,900 shares, representing 3.67% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund has generated a floating profit of approximately 825,200 CNY today and 1,052,700 CNY during the three-day increase [2][5]. - The Xinda Health China Mixed A Fund was established on August 18, 2017, with a current size of 409 million CNY. Year-to-date, it has experienced a loss of 7.67%, ranking 8044 out of 8898 in its category, while it has gained 7.13% over the past year, ranking 5616 out of 8181 [2][5].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under Everbright Pramerica holds a significant position in Tiger Med. The Everbright Pramerica Multi-Strategy Select 18-Month Mixed Fund (004457) held 700 shares in the fourth quarter, representing 0.24% of the fund's net value, ranking it as the ninth largest holding [2][5]. - The fund has realized a floating profit of approximately 1,778 CNY today and a total of 2,268 CNY during the three-day increase [2][5]. - The Everbright Pramerica Multi-Strategy Select 18-Month Mixed Fund was established on May 16, 2017, with a current size of 16.77 million CNY. Year-to-date returns are 0.89%, with a one-year return of 6.02%, and a cumulative return since inception of 43.92% [2][5]. Fund Manager Performance - The fund manager, Zhu Jiantao, has been in position for 1 year and 326 days, managing assets totaling 1.695 billion CNY, with the best return during his tenure being 58.56% and the worst being -0.26% [3][6]. - Co-manager Yao Shi has been in position for 3 years and 92 days, managing assets of 99.14 million CNY, with the best return of 13.48% and the worst of -4.18% during his tenure [3][6].

Core Viewpoint - Tiger Med has seen a significant stock price increase, with a 5% rise on March 27, bringing the share price to 53.32 yuan, and a total market capitalization of 459.10 billion yuan. The stock has risen for three consecutive days, accumulating a total increase of 6.82% during this period [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products. Its business scope includes I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical document translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company's main business includes: clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other supplementary services (2.19%) [1][4]. Fund Holdings - According to data, one fund under Rongtong Fund holds a significant position in Tiger Med. The Rongtong Healthcare Industry Mixed A/B Fund (161616) held 604,700 shares in the fourth quarter, accounting for 5.07% of the fund's net value, making it the second-largest holding. The estimated floating profit for today is approximately 1.54 million yuan, with a total floating profit of 1.96 million yuan during the three-day increase [2][5]. - The Rongtong Healthcare Industry Mixed A/B Fund was established on July 26, 2012, with a current scale of 599 million yuan. Year-to-date, the fund has experienced a loss of 2.95%, ranking 6478 out of 8898 in its category. Over the past year, it has gained 5.27%, ranking 6075 out of 8181, and since inception, it has achieved a return of 117.98% [2][5].

Core Viewpoint - Tiger Medical has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market trend for the company [1][4]. Company Overview - Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company is located in Hangzhou, Zhejiang Province, and specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - A fund under Shangyin Asset Management holds a significant position in Tiger Medical, with 69,700 shares representing 5.56% of the fund's net value, making it the third-largest holding [2][5]. - The fund, named Shangyin High-Quality Preferred 9-Month Holding Period Mixed A (013358), has a total scale of 64.89 million CNY and has experienced a loss of 2.83% this year, ranking 6408 out of 8898 in its category [2][5]. Fund Manager Performance - The fund manager, Chen Bo, has been in charge for 6 years and 55 days, managing assets totaling 841 million CNY. During his tenure, the best fund return was 93.67%, while the worst was -19.42% [3][7].

3月27日，泰格医药涨5%，截至发稿，报53.32元/股，成交6.95亿元，换手率2.35%，总市值459.10亿 元。泰格医药股价已经连续3天上涨，区间累计涨幅6.82%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 从基金十大重仓股角度 数据显示，博时基金旗下5只基金重仓泰格医药股票，合计持有泰格医药153.78万股，按前一日收盘 50.78元，今日截止发稿股价53.32元计算，日浮盈390.6万元。连续3天上涨期间浮盈赚取498.24万元。 | 基金名称 | 基金代 | 基金 | 持股数 | 占流通股比 | 占基金净值 | 持股数 ...

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Shareholder Insights - The Huabao CSI Medical ETF (512170) is among the top ten circulating shareholders of Tiger Med, having reduced its holdings by 2.11% to 14.568 million shares in the third quarter, resulting in a floating profit of approximately 37.03 million CNY today [2][6]. - Over the three-day increase, the floating profit for the ETF has reached 47.20 million CNY [2][6]. Fund Performance - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a current scale of 25.26 billion CNY. It has experienced a loss of 6.22% this year, ranking 4644 out of 5563 in its category [7]. - The fund manager, Zhang Fang, has been in position for 5 years and 59 days, with the fund's total assets amounting to 35.43 billion CNY. The best return during his tenure is 57.19%, while the worst is -23.7% [3][7]. Fund Holdings - The Huabao CSI Medical ETF (512170) increased its holdings in Tiger Med by 126.14 million shares in the fourth quarter, now holding 15.8293 million shares, which constitutes 3.55% of the fund's net value, making it the sixth-largest holding [4][8]. - The floating profit from this position today is approximately 40.21 million CNY, with a total floating profit of 51.29 million CNY over the three-day increase [4][8].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [5]. Fund Holdings - Three funds under Qianhai Kaiyuan hold a total of 2.0321 million shares of Tiger Med, with a floating profit of approximately 5.1614 million CNY based on the stock price increase [2][6]. - The largest holding is from Qianhai Kaiyuan Medical Health A, which holds 1.81 million shares, representing 9.38% of the fund's net value, with a floating profit of about 4.5974 million CNY [3][7]. - Qianhai Kaiyuan Public Health Stock A holds 206,500 shares, accounting for 8.98% of the fund's net value, with a floating profit of approximately 524,500 CNY [3][8]. - Qianhai Kaiyuan CSI Health Index holds 15,566 shares, representing 1.17% of the fund's net value, with a floating profit of around 39,500 CNY [3][8].